BioPorto A/S Reveals Key Financial Outcomes for Q3 2025
In a recent announcement, BioPorto A/S, recognized for its innovative contributions to in vitro diagnostics, presented its key financial results for the third quarter of 2025. The report reflects continued growth in sales and a notable adjustment in financial guidance for the rest of the fiscal year.
Highlighting Financial Achievements
During the third quarter of 2025, BioPorto A/S achieved remarkable results, with a total revenue of DKK 10.4 million. This marks a 7% increase compared to the same period in the previous year, further illustrating a 10% gain at constant exchange rates. Notably, NGAL sales have reached DKK 7.2 million, showing a global growth of 5% and an impressive 10% at constant exchange rates.
Growth in US Market
The surge continues with a robust 20% increase in sales within the US NGAL Research Use Only (RUO) sector compared to Q3 2024. When adjusted for constant exchange rates, this figure rises to 27%. Such performance is indicative of BioPorto's strong foothold in the US diagnostic market.
Global Sales Analysis
Despite strong performances in specific markets, NGAL sales in other regions saw a significant decrease, plummeting by 87% due to the previous year's bulk order that skewed comparisons. Nevertheless, ProNephro AKI™ (NGAL) sales through distributors in Q3 accounted for DKK 2.1 million, underscoring the brand's resilience amidst market fluctuations.
Dive into the Financial Metrics
The adjusted EBITDA loss for the quarter stood at DKK 16.8 million, a decrease from the DKK 19.6 million loss reported the prior year. This outcome aligns with expectations, showcasing prudent fiscal management from the company. Moreover, by September 30, 2025, BioPorto maintained a cash position of DKK 27.6 million, a reduction from DKK 76.3 million in the same quarter last year.
Revised Guidance for Full Year 2025
With ongoing evaluations of performance, BioPorto is revising its guidance for 2025. The updated total revenue expectation now falls in the range of DKK 40-45 million, down from a previously anticipated DKK 45-50 million. Meanwhile, the adjusted EBITDA loss guidance remains stable at DKK 75-80 million.
Monthly Revenue Insights
For the first nine months of 2025, total revenue reached DKK 28.7 million. While this reflects a modest 1% increase year-over-year, advances at constant exchange rates show a 2% increase. A stark contrast is observed in NGAL sales, which rose by 5% compared to last year, notably bolstered by strong US RUO sales.
Global Challenges
On the other hand, international sales of NGAL saw a considerable drop of 49% year to date, primarily influenced by last year's bulk orders. This data emphasizes the fluctuating dynamics in global markets and the need for strategic adjustments.
Looking Ahead
BioPorto is set to release a full interim report detailing these findings on November 19, 2025. Stakeholders and interested parties are encouraged to stay informed about company announcements and press releases through BioPorto's investor contact page.
About BioPorto A/S
BioPorto is an influential player in the field of in vitro diagnostics, committed to saving patients’ lives with groundbreaking kidney biomarkers. These tools are crucial for helping healthcare professionals enhance patient management. Signature products focus on Acute Kidney Injury (AKI), facilitating faster and more efficient patient assessments, ultimately leading to improved health outcomes.
The company is strategically positioned with facilities in both Copenhagen and Boston, signifying a strong international presence. BioPorto A/S is proud to be listed on the Nasdaq Copenhagen stock exchange, showcasing its commitment to transparency and growth.
Frequently Asked Questions
What were the key financial highlights for BioPorto A/S in Q3 2025?
BioPorto A/S reported a revenue of DKK 10.4 million for Q3 2025, marking a 7% increase from the prior year, alongside strong growth in US NGAL sales.
How has the US market impacted BioPorto's sales growth?
The US NGAL Research Use Only (RUO) sales experienced a significant growth of 20% in Q3 2025, contributing positively to the company’s overall performance.
What is the updated revenue guidance for BioPorto in 2025?
BioPorto has revised its revenue guidance for 2025 to a range of DKK 40-45 million, down from the previous estimate of DKK 45-50 million.
What challenges did BioPorto face in international NGAL sales?
International NGAL sales decreased by 49% year to date, primarily due to the absence of large bulk orders that occurred in the previous year.
How is BioPorto addressing its financial performance?
BioPorto is proactively adjusting its financial guidance and focusing on key markets to improve its sales performance while managing its adjusted EBITDA loss expectations.
